Stockscreener 앱 받기
3.24
3.85%
0.12
시장 영업 전:
3.17
-0.07
-2.16%
Anavex Life Sciences Corporation 주식(AVXL)의 최신 뉴스
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology between Autism and Alzheimer's disease - marketscreener.com
Anavex Life Sciences Teases New Pivotal Blarcamesine Trials, Maps Regulatory Path at Needham Conference - MarketBeat
Anavex Life Sciences Advances Blarcamesine Research, Highlighting Shared Autophagy Mechanisms in Autism and Alzheimer’s Disease - Quiver Quantitative
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease - Anavex Life Sciences
Aug Rallies: Does Anavex Life Sciences Corp have strong fundamentalsMarket Activity Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Anavex Life Sciences Corp. (AVXL) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Shareholders to Connect - ACCESS Newswire
AVXL Technical Analysis | Trend, Signals & Chart Patterns | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Anavex Life Sciences Corp. (AVXL) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Aug Retail: Is Anavex Life Sciences Corp stock trending bullish2026 Short Interest & Reliable Volume Spike Alerts - baoquankhu1.vn
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Anavex Life Sciences Corp. to Present at 25th Annual Needham Virtual Healthcare Conference - Quiver Quantitative
AVXL Stock Price, Quote & Chart | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Anavex Life Sciences Corp. (AVXL) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-04-05 | Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:AVXL | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Investors to Connect - ACCESS Newswire
Anavex Life Sciences Corp. (AVXL) stock price, news, quote and history - Yahoo Finance UK
2026-04-03 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Investors to Connect | NDAQ:AVXL | Press Release - stockhouse.com
3 Promising Penny Stocks With At Least $200M Market Cap - Sahm
Bronstein, Gewirtz & Grossman, LLC Encourages Anavex Life Sciences Corp. (AVXL) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Anavex Life Sciences Corp (12X1.HM) Recent Insider Transactions - Yahoo! Finance Canada
AVXL Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Anavex Life Sciences' (AVXL) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Anavex Life Sciences Provides Comprehensive Regulatory Update - The Manila Times
After withdrawing its EU filing, Anavex keeps Alzheimer’s drug in talks - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Stockholders to Connect - ACCESS Newswire
Anavex Life Sciences stock crushed as European Alzheimer's drug filing pulled after EMA pushback - MSN
Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-03-27 | Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:AVXL | Press Release - Stockhouse
Anavex Life Sciences Under Investigation for Securities Fraud - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - PR Newswire
Vanguard reports 0 AVXL shares after internal realignment (AVXL) - Stock Titan
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings - Sahm
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback - Sahm
Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip? - Yahoo Finance
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation - Yahoo Finance
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
AVXL Plummets 31% to 52-Week Lows: A Technical Meltdown Ignites the Biotech Watchlist - Bitget
Anavex Life Sciences withdraws EU marketing application for blarcamesine after CHMP feedback - TradingView
Anavex (NASDAQ: AVXL) withdraws EU Alzheimer’s drug application for blarcamesine - Stock Titan
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast - Benzinga
Anavex Life Sciences Corp Faces Competitive Pressure Amid Financial Year Results - StocksToTrade
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease - Bitget
Anavex Life Sciences Corp. (AVXL) recently disclosed the latest updates on the regulatory review of its investigational drug Blarcamesine for early Alzheimer’s disease in the European Union. - Bitget
AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug - Stocktwits
Anavex Life Sciences provides update on regulatory review in the EU for blarcamesine to treat early Alzheimer's disease - marketscreener.com
Anavex Life Sciences stock tumbles after EU filing withdrawal By Investing.com - Investing.com Australia
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease - The Manila Times
Anavex Life Sciences stock tumbles after EU filing withdrawal - Investing.com
EU review halts Anavex’s Alzheimer’s drug bid, more data next - Stock Titan
2.69%
0.25%
자본화:
|
볼륨(24시간):